{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053384","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2026-08-05T20:17:15+00:00","discovered_at":"2026-08-05T20:19:02.170553+00:00","generated_at":"2026-08-05T20:20:52.268102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evolus Q2 revenue $84.1M (+21% YoY); raises FY2026 guidance; adds Profhilo U.S. rights","bullets":["Q2 net revenue $84.1M (+21% YoY); GAAP operating loss $4.5M; adjusted EBITDA $4.7M (vs -$7.9M prior year).","Raises FY2026 revenue guidance to $330-337M; raises adjusted gross margin to 67.0-67.5%; narrows non-GAAP opex to $212-216M.","Exclusive U.S. partnership for Profhilo (IBSA); peak revenue >$100M; U.S. launch expected 2030.","Expands Estyme HA gel franchise into Canada, Australia, New Zealand; commercialization expected 2028.","Cash $45.2M; $120M non-dilutive capacity; reaffirms 2028 outlook ($450-500M revenue, 13-15% adj EBITDA margin)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053384","json":"https://secwatch.observer/filing/0001628280-26-053384.json","markdown":"https://secwatch.observer/filing/0001628280-26-053384.md","text":"https://secwatch.observer/filing/0001628280-26-053384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/0001628280-26-053384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/eols-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:20:52.268102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}